Tannic acid chitosan iron oxide nanocomposite for cervical cancer treatment

[Display omitted] •A novel anticancer nanodrug, tannic acid-polymer-iron oxide was constructed.•The superparamagnetic nanocomposite had a mean size of 9 nm with controlled release feature.•The nanocomposite treatment remarkably inhibited cell growth in the cervical cancer HeLa cells.•This nanocompos...

Full description

Saved in:
Bibliographic Details
Published in:Inorganic chemistry communications 2024-04, Vol.162, p.112160, Article 112160
Main Authors: Barahuie, Farahnaz, Dorniani, Dena, Saifullah, Bullo, Arulselvan, Palanisamy, Hussein, Mohd Zobir, Jaganathan, Ravindran, Pratiwi, Ariyati Retno
Format: Article
Language:English
Subjects:
Cervical cancer
Chitosan-iron oxide nanoparticles
Drug delivery
Nanocomposite
Sustained release
Tannic acid
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] •A novel anticancer nanodrug, tannic acid-polymer-iron oxide was constructed.•The superparamagnetic nanocomposite had a mean size of 9 nm with controlled release feature.•The nanocomposite treatment remarkably inhibited cell growth in the cervical cancer HeLa cells.•This nanocomposite can be a potential anticancer agent for the treatment of cervical cancer. An innocuous and stimuli-responsive nano-vehicle was constructed from chitosan (CTS) and synthesized iron oxide (Fe3O4) nanoparticles. Tannic acid (TNA) was selected as a drug model to attest to the function of CTS-Fe3O4 nano-vehicle in cervical cancer therapy. Fourier transform infrared (FTIR) data disclosed that Fe3O4 nanoparticles could be favourably coated with CTS and TNA in thermally stable and superparamagnetic TNA-CTS-Fe3O4 nanocomposite (saturation magnetization of 41.1 emu/g) while the CTS-Fe3O4 nano-vehicle afforded a perfect microenvironment for efficient loading (10.5 %) and controlled release of TNA. Intriguingly, in vitro release profiles for TNA-CTS-Fe3O4 nanocomposite at pH 5 and 7.4 were governed properly with a pseudo-second-order kinetic model and the pH value influenced the TNA release profiles with a cumulative release percentage of 90 % within 1892 min at a pH of 5 and 79 % within 3915 min at a pH of 7.4. What is more, the treatment with TNA-CTS-Fe3O4 nanocomposite with a mean diameter of 9 nm, substantially reduced the cell growth and induced apoptosis in the cervical cancer HeLa cells. Therefore, it was verified that the TNA-CTS-Fe3O4 nanocomposite could be a potential anticancer agent for the treatment of cervical cancer with distinctive physicochemical features.
ISSN:1387-7003
1879-0259
DOI:10.1016/j.inoche.2024.112160